Incretin analog tri-receptor agonist compositions for weekly dosing

ChangeBridge: Patent Apps - Therapeutics (A61P)

Published April 2nd, 2026

Detected April 2nd, 2026

Summary

USPTO published patent application US20260091087A1 disclosing dosing regimens and compositions for long-acting incretin analog tri-receptor agonists targeting GIP, GLP-1, and glucagon receptors for once-weekly administration. The application (No. 19393199) was filed November 18, 2025, and names Tamer Coskun, Zvonko Milicevic, and Shweta Urva as inventors.

View original document View source feed page

What changed

USPTO published a patent application covering methods and compositions for administering incretin analog tri-receptor agonists suitable for once-weekly dosing. The invention relates to GIP, GLP-1, and glucagon (GGG) tri-receptor agonists with extended duration of action. The application is classified under A61K 38/26, A61P 3/04 (anti-obesity), and A61P 3/10 (anti-diabetic). This represents an incremental advance in GLP-1-based therapeutics for metabolic disorders.

This is a patent application publication only and does not impose compliance obligations. Pharmaceutical companies developing GLP-1 or dual/triple agonist therapeutics may review the disclosed claims to assess potential freedom-to-operate considerations or identify areas for design-around. No regulatory action or filing is required. Patent prosecution will proceed through standard USPTO examination procedures.

Source document (simplified)

← USPTO Patent Applications

METHODS OF USING AND COMPOSITIONS INCLUDING AN INCRETIN ANALOG

Application US20260091087A1 Kind: A1 Apr 02, 2026

Inventors

Tamer COSKUN, Zvonko MILICEVIC, Shweta URVA

Abstract

Doses and dosing regimens for incretin analogs are disclosed comprising determining and administering doses of long-acting incretin analogs suitable for once-weekly dosing, such as a glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1) and glucagon (GCG) (GGG) tri-receptor agonist.